Natco Pharma shares surged sharply on the BSE, currently trading at RS 885.35, up by 63.25 points or 7.69% compared to its previous close of RS 822.10.

The stock opened at RS 825.05 and touched an intraday high of RS 895.00 and a low of RS 825.05. A total of 382 shares have been traded so far on the counter.

The BSE Group ‘A’ stock with a face value of RS 2 had earlier touched a 52-week high of RS 1059.60 on July 24, 2025, and a 52-week low of RS 660.05 on April 7, 2025. Over the past week, the scrip recorded a high of RS 895.00 and a low of RS 815.05. The company’s current market capitalization stands at RS 14724.62 crore.

In terms of shareholding pattern, promoters hold 49.48% stake in the company, while Institutional investors and Non-Institutional investors hold 20.54% and 29.97% respectively.

The rally comes after the company received approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market a generic version of Semaglutide Injection in India. The company plans to launch the product in March 2026. Semaglutide is prescribed for adults with inadequately controlled type 2 diabetes mellitus and is used alongside diet and exercise.

Natco Pharma was originally incorporated as a private company and operates in the research, development, manufacturing, and marketing of pharmaceutical substances and finished dosage formulations for both domestic and international markets.